|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:alsoKnownAs
|
gptkb:3,4-methylenedioxymethamphetamine
gptkb:MDMA
|
|
gptkbp:aroma
|
slight chemical odor
|
|
gptkbp:category
|
Hallucinogen
entactogen
recreational drug
stimulant
|
|
gptkbp:chemicalClass
|
amphetamine
|
|
gptkbp:color
|
varies (often colored tablets)
|
|
gptkbp:commonAdulterants
|
gptkb:PMMA
amphetamine
caffeine
|
|
gptkbp:controlledSubstanceAct
|
yes
|
|
gptkbp:countryOfOrigin
|
gptkb:Germany
|
|
gptkbp:discoveredBy
|
gptkb:Merck
|
|
gptkbp:discoveredIn
|
1912
|
|
gptkbp:duration
|
3-6 hours
|
|
gptkbp:effect
|
enhanced sensory perception
euphoria
increased empathy
increased sociability
|
|
gptkbp:eliminationHalfLife
|
7-9 hours
|
|
gptkbp:firstPopularUse
|
gptkb:1980s_rave_culture
|
|
gptkbp:flavor
|
bitter
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ecstasy
|
|
gptkbp:legalStatus
|
illegal in most countries
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
seizures
hyperthermia
hyponatremia
|
|
gptkbp:prohibits
|
gptkb:UN_Convention_on_Psychotropic_Substances
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
addiction potential
neurotoxicity
|
|
gptkbp:routeOfAdministration
|
oral
insufflation
|
|
gptkbp:scheduledUnder
|
gptkb:Schedule_I_(US)
|
|
gptkbp:sideEffect
|
anxiety
dehydration
insomnia
hyperthermia
jaw clenching
|
|
gptkbp:streetForm
|
gptkb:tablet
capsule
powder
|
|
gptkbp:target
|
gptkb:dopamine_transporter
gptkb:norepinephrine_transporter
gptkb:serotonin_transporter
|
|
gptkbp:therapeuticResearch
|
PTSD treatment
anxiety in terminal illness
|
|
gptkbp:toxicity
|
high in overdose
|
|
gptkbp:usedFor
|
recreational purposes
|
|
gptkbp:bfsParent
|
gptkb:Hedy_Lamarr
gptkb:Avant
gptkb:Maxfield_Parrish
gptkb:Hedy_Kiesler_Markey
|
|
gptkbp:bfsLayer
|
5
|